Cyclic Nucleotide Phosphodiesterases

Since the last major compendium dedicated to cyclic nucleotide phosphodiesterases (PDEs) was published over 15 years ago, an enormous amount of progress has occurred in the field. There is great need for a centralized source for key information in this burgeoning and therapeutically important area of medical research. Cyclic Nucleotide Phosph

Showcasing the recent progresses of the field, Cyclic Nucleotide Signaling covers the major tools and methodologies used in various areas of research. The majority of the chapters are protocol oriented, with the goal of providing clear directions for laboratory use. Students and investigators new to the field will find this book particularly informative, as will scientists already actively researching nucleotide signaling.

This book reviews advances in understanding phosphodiesterases within the central nervous system and their therapeutic applications. A range of expert authors from both academia and industry describe these, then focus on the areas of greatest scientific and medical interest to provide more detailed coverage. Therapeutic and drug discovery applications are covered for diseases including Alzheimer's, Parkinson's, schizophrenia, erectile dysfunction, and spinal cord injuries. There is also a chapter on drug discovery tools such as in vitro assays and X-ray structures for medicinal chemistry studies.

Bioenvironmental Issues Affecting Men's Reproductive and Sexual Health is structured into two parts related to men’s reproductive and sexual health with eight sections designed to enable a logical flow of such knowledge. The book is focused on the biology of key organs involved in male reproduction and the environmental influences affecting their functions with particular emphasis on clinical aspects. Individual chapters within the book range from basic to translational aspects, but all hold clinical relevance. This is an essential reference for those working and learning in the field of human reproduction, reproductive toxicology and environmental influences on reproductive and sexual health. Brings together the leading authorities working in the field of male reproduction and sexual health and how the environment affects these issues Provides guidelines and reference values of various reproductive hormones, semen parameters, inclusion/exclusion criteria for clinical trials Discover the most efficient methods by which to design clinical protocols for sperm safety studies and reproductive toxicology trials

Second volume in a series addressing topical areas important to the understanding of the control of biological processes. This volume focuses on the structure and molecular biology of isoenzymes and their role in signal transduction processes necessary for co-ordinating cellular functioning.

Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable PDE inhibitor for their research or who is dealing with such drugs in a clinical setting. Utilizes actual testing and research of new PDE inhibitors Valuable for researchers and students alike

Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacological intervention. Multiple PDE genes, isoform diversity, selective expression and compartmentation of the isoforms, and an array of conformations of PDE proteins are properties that challenge development of drugs that selectively target this class of enzymes. Novel characteristics of PDEs are viewed as unique opportunities to increase specificity and selectivity when designing novel compounds for certain therapeutic indications. This chapter provides a summary of the major concepts related to the design and use of PDE inhibitors.

Research leaders in the PDE field describe new concepts and techniques for investigating the role of PDEs in orchestrating normal and pathophysiological responses. Presented in step-by-step detail, these readily reproducible methods allow the measurement of cyclic nucleotide variations in living cells, as well as their visualization in a spatio-temporal manner, the localization and characterization of their activities in tissues and living cells, and the assessment of targeted PDEs in creating specific tools and drugs.

PDEs are a family of enzymes that catalyze the hydrolysis of intracellular cyclic nucleotides. They are implicated in a number of disorders and dysfunctions and PDE inhibitors have already proven to be effective therapies for erectile dysfunction, COPD, and psoriatic arthritis. This family of enzymes also plays a role in diseases and disorders of the CNS such as depression, anxiety, schizophrenia, and Alzheimer's Disease. Unfortunately no effective PDE inhibitors have been developed for the treatment of these diseases. The proposed book will be a comprehensive overview of the current state of basic and translational research on PDE inhibitors written by internationally recognized experts. Authors will also discuss potential PDE subtypes and splice variants in the hopes that this will spur more creative approaches to PDE targeting drugs.

In the present volume of the Handbook of Experimental Pharmacology well known experts describe the actions of different xanthines with a focus on caffeine and theophylline. A special chapter is devoted to theobromine, an active component of chocolate, the actions of which are less well characterized. This book also presents the pharmacology of one xanthine derivative, propentofylline, as an example of a xanthine that has gone through extensive development for a novel therapeutic area.